# A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)

> **NCT01049282** · PHASE1 · COMPLETED · sponsor: **Statens Serum Institut** · enrollment: 39 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** Antigen (Ag85B-ESAT-6)
- **BIOLOGICAL:** Antigen (Ag85B-ESAT-6) with adjuvant (IC31)

## Key facts

- **NCT ID:** NCT01049282
- **Lead sponsor:** Statens Serum Institut
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01049282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01049282, "A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01049282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*